Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The investigators previously showed that the use of a high-dose intravenous PPI regimen after
endoscopic control of bleeding from peptic ulcers reduced rate of recurrent bleeding,
decreased the need for endoscopic and surgical interventions and in general improved
patients' outcomes. A trend towards reduced mortality associated with the use of high-dose
intravenous PPI was also observed. Recent clinical trials from Asia have provided evidence
that high-dose oral PPIs are associated with a reduction in rebleeding. Current meta-analysis
suggests that both high dose (intravenous) and low dose (oral) PPIs effectively reduce
rebleeding vs placebo. However, there has been no clinical study to compare IV infusion to
oral PPI in this patient population.
The purpose of this clinical study is to compare the efficacy and safety of intravenous and
oral Esomeprazole in patients with peptic ulcer hemorrhage who are at risk for recurrent
bleeding. The investigators hypothesize that using IV infusion is superior to oral PPI.